Search

Your search keyword '"Ibrahim, Tareq"' showing total 3 results
Start Over Author "Ibrahim, Tareq" Topic coronary angiography Topic percutaneous coronary intervention
3 results on '"Ibrahim, Tareq"'

1. Be prepared for the unexpected: Mind‐stretching in ST‐elevation myocardial infarction with situs inversus totalis.

Author

Viggiani, Giacomo, Ibrahim, Tareq, Allescher, Julia, and Steger, Alexander

Subjects
*SITUS inversus, *ST elevation myocardial infarction, *BRUGADA syndrome, *MYOCARDIAL infarction, *CORONARY angiography, *PERCUTANEOUS coronary intervention
Abstract

Key Clinical Message: Situs inversus totalis is a rare diagnosis, but the likelihood of experiencing myocardial infarction is presumed to be comparable to the general population average. In individuals exhibiting situs inversus with suspected myocardial infarction, ECG recording, including right precordial leads, is crucial for diagnostic assessment. Coronary angiography and intervention should be performed with standard equipment using inverted maneuvers and radiographic projections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial

Author

Harada, Yukinori, Colleran, Roisin, Kufner, Sebastian, Giacoppo, Daniele, Rheude, Tobias, Michel, Jonathan, Cassese, Salvatore, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert A.

Subjects
Male, Time Factors, Endocrinology, Diabetes and Metabolism, Myocardial Infarction, Kaplan-Meier Estimate, Coronary Angiography, Prosthesis Design, Disease-Free Survival, Coronary Restenosis, Percutaneous Coronary Intervention, Risk Factors, Drug-Eluting Stent, Humans, cardiovascular diseases, Original Investigation, Aged, Proportional Hazards Models, Sirolimus, Coronary Thrombosis, Diabetes, Cardiovascular Agents, Drug-Eluting Stents, Middle Aged, equipment and supplies, Probucol, Treatment Outcome, surgical procedures, operative, Cardiovascular Diseases, Retreatment, Female, Zotarolimus, Cardiology and Cardiovascular Medicine, Diabetic Angiopathies, Platelet Aggregation Inhibitors
Abstract

Background Improved outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention remain an unmet clinical need. We assessed the long-term efficacy and safety of novel polymer-free sirolimus- and probucol-eluting stent in diabetic patients enrolled in intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents 5 trial. Methods In a pre-specified subgroup analysis, outcomes of diabetic patients treated with a sirolimus- and probucol-eluting stent or a second-generation zotarolimus-eluting stent were compared. The primary endpoint was a device-oriented composite outcome comprising cardiac death, target vessel-related myocardial infarction (MI), or target lesion revascularization (TLR) at 5-year follow-up. Event-free survival was assessed using the Kaplan–Meier method. Hazard ratios (HR) and 95 % confidence intervals (CI) were estimated from univariate Cox proportional hazards models. Results A total of 870 patients with diabetes mellitus were treated with either a sirolimus- and probucol-eluting stent (n = 575) or a second-generation zotarolimus-eluting stent (n = 295). At 5 years, the rate of device-oriented composite endpoint was comparable between the sirolimus- and probucol-eluting stent and the second-generation zotarolimus-eluting stent (32.9 versus 33.4 %, HR 0.88, 95 % CI 0.76–1.26). No significant differences were observed between the sirolimus- and probucol-eluting stent and the second-generation zotarolimus-eluting stent groups in the incidence of cardiac death (15.6 versus 16.7 % HR 0.92, 95 % CI 0.63–1.32), target-vessel MI (4.6 versus 6.6 %, HR 0.73, 95 % CI 0.40–1.34), and TLR (18.6 versus 18.8 %, HR 1.00, 95 % CI, 0.72–1.41). The rate of definite or probable stent thrombosis was low and similar in both groups (2.5 versus 2.6 %, HR 1.02, 95 % CI, 0.41–2.52). Conclusions In patients with diabetes the long-term efficacy and safety of a polymer-free sirolimus- and probucol-eluting stent were comparable to a second-generation durable polymer zotarolimus-eluting stent. Trial registration ClinicalTrials.gov NCT00598533. Registered 10 January 2008

Full Text
View/download PDF

3. TCT-483 Angiographic and two-year clinical outcomes following percutaneous coronary intervention for in-stent restenosis of polymer-free sirolimus- and probucol-eluting stent compared with durable polymer zotarolimus-eluting stent.

Author

Harada, Yukinori, Colleran, Roisin, Kufner, Sebastian, Giacoppo, Daniele, Rheude, Tobias, Michel, Jonathan, Wiebe, Jens, Cassese, Salvatore, Ibrahim, Tareq, Laugwitz, Karl-Ludwig, Kastrati, Adnan, and Byrne, Robert

Subjects
*CORONARY restenosis, *CORONARY angiography, *PERCUTANEOUS coronary intervention, *RAPAMYCIN, *MEDICAL polymers, *SURGICAL stents, *DRUG-eluting stents, *THERAPEUTICS
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results